keyword
MENU ▼
Read by QxMD icon Read
search

DOSE DENSE BREAST CANCER CHEMOTHERAPY

keyword
https://www.readbyqxmd.com/read/30099601/real-world-use-of-granulocyte-colony-stimulating-factor-in-ambulatory-breast-cancer-patients-a-cross-sectional-study
#1
Florence Van Ryckeghem, Chloë Haverbeke, Wim Wynendaele, Guy Jerusalem, Luc Somers, Anke Van den Broeck, Sofie Vingerhoedt, Simon Van Belle
PURPOSE: To prevent febrile neutropenia (FN), European Organisation for Research and Treatment of Cancer (EORTC) guidelines recommend primary prophylaxis with granulocyte colony-stimulating factors (PPG) for patients at high risk (≥ 20%) of FN. In Belgium, the use of PPG is restricted by specific reimbursement criteria. The impact of these criteria on PPG use and adherence to guidelines is unknown. METHODS: This multicentre, cross-sectional, observational study aimed to describe PPG use by FN risk category in breast cancer patients who were scheduled to receive myelosuppressive chemotherapy in outpatient clinics in Belgium during a 2-week period between 13 October and 12 December 2014...
August 11, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/30040817/randomised-feasibility-trial-to-compare-three-standard-of-care-chemotherapy-regimens-for-early-stage-triple-negative-breast-cancer-react-tnbc-trial
#2
John Hilton, Carol Stober, Sasha Mazzarello, Lisa Vandermeer, Dean Fergusson, Brian Hutton, Mark Clemons
INTRODUCTION: Despite the importance of chemotherapy in the treatment of early stage triple negative breast cancer (TNBC), no one optimal regimen has been identified. We conducted a pilot trial comparing outcomes for the three most commonly used chemotherapy regimens to assess the feasibility of conducting a larger definitive trial. METHODS: Using integrated consent, newly diagnosed TNBC patients were randomised to one of three standard regimens: dose-dense doxorubicin-cyclophosphamide then paclitaxel, doxorubicin-cyclophosphamide then weekly paclitaxel or 5-FU-epirubicin-cyclophosphamide then docetaxel...
2018: PloS One
https://www.readbyqxmd.com/read/30040523/double-blind-phase-iii-trial-of-adjuvant-chemotherapy-with-and-without-bevacizumab-in-patients-with-lymph-node-positive-and-high-risk-lymph-node-negative-breast-cancer-e5103
#3
Kathy D Miller, Anne O'Neill, William Gradishar, Timothy J Hobday, Lori J Goldstein, Ingrid A Mayer, Stuart Bloom, Adam M Brufsky, Amye J Tevaarwerk, Joseph A Sparano, Nguyet Anh Le-Lindqwister, Carolyn B Hendricks, Donald W Northfelt, Chau T Dang, George W Sledge
Purpose Bevacizumab improves progression-free survival but not overall survival in patients with metastatic breast cancer. E5103 tested the effect of bevacizumab in the adjuvant setting in patients with human epidermal growth factor receptor 2-negative disease. Patients and Methods Patients were assigned 1:2:2 to receive placebo with doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (arm A), bevacizumab only during AC and paclitaxel (arm B), or bevacizumab during AC and paclitaxel followed by bevacizumab monotherapy for 10 cycles (arm C)...
July 24, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30007402/survival-benefit-of-pure-dose-dense-chemotherapy-in-breast-cancer-a-meta-analysis-of-randomized-controlled-trials
#4
REVIEW
Wenqi Zhou, Shizhe Chen, Faliang Xu, Xiaohua Zeng
BACKGROUND: Dose-dense chemotherapy is a widely accepted regimen for high-risk breast cancer patients. However, conflicting survival benefits of pure dose-dense chemotherapy have been reported in different randomized controlled trials (RCTs). This meta-analysis aimed to further assess the efficacy and safety of pure dose-dense chemotherapy in breast cancer. METHODS: A literature search of electronic databases and websites was performed to identify phase III RCTs reporting the efficacy and toxicity of pure dose-dense chemotherapy...
July 14, 2018: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29970577/efficacy-and-safety-of-bi-weekly-pegfilgrastim-for-dose-dense-chemotherapy-induced-neutropenia-in-breast-cancer-patients
#5
Hitomi Mori, Makoto Kubo, Masaya Kai, Kanako Kurata, Mai Yamada, Masafumi Nakamura
BACKGROUND/AIM: The dose-dense doxorubicin and cyclophosphamide (ddAC) for patients with HER-2-negative breast cancer is recommended by the National Comprehensive Cancer Network guideline in US. However, there are little data on serum G-CSF concentrations in patients undergoing bi-weekly dose-dense therapy with pegfilgrastim. The objective of this study was to compare the serum G-CSF concentrations in patients receiving pegfilgrastim in bi- or tri-weekly regimens. PATIENTS AND METHODS: This study included 26 patients who received ddAC or docetaxel and cyclophosphamide (TC) for primary breast cancer...
July 2018: Anticancer Research
https://www.readbyqxmd.com/read/29948957/the-efficacy-and-feasibility-of-dose-dense-sequential-chemotherapy-for-japanese-patients-with-breast-cancer
#6
Daisuke Takabatake, Yukiko Kajiwara, Shoichiro Ohtani, Yoko Itano, Mari Yamamoto, Shinichiro Kubo, Masahiko Ikeda, Mina Takahashi, Fumikata Hara, Kenjiro Aogi, Shozo Ohsumi, Yutaka Ogasawara, Yoshitaka Nishiyama, Hajime Hikino, Kinya Matsuoka, Yuko Takahashi, Tadahiko Shien, Naruto Taira, Hiroyoshi Doihara
BACKGROUND: Perioperative dose-dense chemotherapy (DDCT) with granulocyte-colony stimulating factor (G-CSF) prophylaxis is a standard treatment for patients with high-risk breast cancer. The approval of this approach in Japan led to the widespread adoption of DDCT, despite limited efficacy and safety data among Japanese patients. We evaluated the efficacy and safety of neoadjuvant DDCT for Japanese patients with breast cancer. METHODS: This prospective, multicenter, phase II study evaluated 52 women with operable human epidermal growth factor receptor 2-negative breast cancer and axillary lymph node metastasis...
June 11, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29937992/neoadjuvant-chemotherapy-in-breast-cancer-a-dose-dense-schedule-in-real-life-and-putative-role-of-pik3ca-mutations
#7
Valentina Cocciolone, Katia Cannita, Alessandra Tessitore, Valentina Mastroiaco, Lucia Rinaldi, Stefania Paradisi, Azzurra Irelli, Paola Lanfiuti Baldi, Tina Sidoni, Enrico Ricevuto, Antonella Dal Mas, Giuseppe Calvisi, Gino Coletti, Antonietta Ciccozzi, Laura Pizzorno, Valter Resta, Alberto Bafile, Edoardo Alesse, Corrado Ficorella
Background: Dose-dense chemotherapy is one of the treatments of choice for neoadjuvant therapy in breast cancer (BC). Activating mutations in PIK3CA gene predict worse response to neoadjuvant chemotherapy for HER2-positive patients, while their role is less clearly defined for HER2-negative tumors. Methods: We conducted a phase I/II study of neoadjuvant, sequential, dose-dense anthracycline/taxane chemotherapy, plus trastuzumab in HER2-positive patients and investigated the correlation of pre-treatment PIK3CA mutation status with pathologic complete response (pCR) and long-term outcome in a real-life setting...
June 8, 2018: Oncotarget
https://www.readbyqxmd.com/read/29895438/phase-2-study-of-dose-dense-doxorubicin-and-cyclophosphamide-followed-by-eribulin-mesylate-with-or-without-prophylactic-growth-factor-for-adjuvant-treatment-of-early-stage-human-epidermal-growth-factor-receptor-2-negative-breast-cancer
#8
Karen A Cadoo, Peter A Kaufman, Andrew D Seidman, Cassandra Chang, Dongyuan Xing, Tiffany A Traina
BACKGROUND: Eribulin has significantly improved overall survival for patients with metastatic breast cancer who received ≥ 2 prior chemotherapy regimens for advanced disease. This trial assessed eribulin as adjuvant therapy for patients with early-stage breast cancer. PATIENTS AND METHODS: Patients with human epidermal growth factor receptor 2-negative, stage I to III breast cancer received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 provided intravenously on day 1 of each 14-day cycle for 4 cycles, with pegfilgrastim on day 2, followed by 4 cycles of eribulin mesylate 1...
April 7, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29800932/evaluation-of-tolerability-and-efficacy-of-incorporating-carboplatin-in-neoadjuvant-anthracycline-and-taxane-based-therapy-in-a-brca1-enriched-triple-negative-breast-cancer-cohort
#9
Tal Sella, Einav Nili Gal Yam, Keren Levanon, Tal Shapira Rotenberg, Moran Gadot, Iryna Kuchuk, Rinat Bernstein Molho, Amit Itai, Tami Mekel Modiano, Raya Gold, Bella Kaufman, Shani Paluch Shimon
PURPOSE: The addition of carboplatin (Cb) to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) has been demonstrated to improve pathologic complete response (pCR) at the expense of increased toxicity. We aimed to evaluate the effectiveness and tolerability of dose-dense anthracycline & cyclophosphamide (ddAC) followed by weekly paclitaxel (wT) in combination with weekly Cb. METHODS: Retrospective data was collected on patients with clinical stage I-III TNBC treated with neoadjuvant ddAC-wTCb (four cycles of ddA 60 mg/m2 and ddC 600 mg/m2 every 2 weeks followed by 12 cycles of wT 80 mg/m2 with Cb AUC 1...
August 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29514832/rare-case-of-metaplastic-breast-cancer-in-a-man
#10
Heather Katz, Hassaan Jafri, Thomas Dougherty, Yehuda Lebowicz
Metaplastic breast cancer (MBC) in men is an extremely rare entity. MBC is typically very aggressive with a poor prognosis. In men, it has only been reported three times in the literature. We report a 47-year-old man who presented with right-sided breast erythema and nipple inversion. Mammogram revealed a 2.4 cm spiculated mass. Initial pathology was inconclusive; however, right-sided simple mastectomy showed invasive metaplastic carcinoma with adenosquamous histology. He received adjuvant chemotherapy with 4 cycles of dose dense Adriamycin and cyclophosphamide followed by 12 weeks of paclitaxel and chest wall radiation...
March 7, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29468855/major-clinical-research-advances-in-gynecologic-cancer-in-2017
#11
REVIEW
Dong Hoon Suh, Miseon Kim, Kyung Hun Lee, Keun Yong Eom, Maj Kamille Kjeldsen, Mansoor Raza Mirza, Jae Weon Kim
In 2017, 10 topics were selected as major clinical research advances in gynecologic oncology. For cervical cancer, efficacy and safety analysis results of a 9-valent human papillomavirus (HPV) vaccine and long-term impact of reduced dose of quadrivalent vaccine were updated. Brief introduction of KEYNOTE trials of pembrolizumab, a monoclonal antibody that blocks the interaction between programmed death (PD)-1 and its ligands, PD-L1 and PD-L2, followed. Tailored surveillance programs for gynecologic cancer related with Lynch syndrome and update on sentinel lymph node mapping were reviewed for uterine corpus cancer...
March 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29423899/influence-of-control-group-therapy-on-the-benefit-from-dose-dense-chemotherapy-in-early-breast-cancer-a-systemic-review-and-meta-analysis
#12
REVIEW
Hadar Goldvaser, Habeeb Majeed, Domen Ribnikar, Boštjan Šeruga, Alberto Ocaña, David W Cescon, Eitan Amir
PURPOSE: Results from clinical trials of adjuvant dose-dense chemotherapy in patients with breast cancer are inconsistent. METHODS: A systematic search of MEDLINE identified studies comparing the efficacy of dose-dense adjuvant chemotherapy to a standard treatment. The primary analysis included studies that used identical regimens in the experimental and control groups, but varied only dose density. A secondary analysis included studies that used either different drugs or doses in the experimental and the control groups...
June 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29384935/internal-mammary-sentinel-lymph-node-biopsy-with-modified-injection-technique-a-case-report
#13
Zhao Bi, Wei-Zhen Zheng, Heng Qiu, Peng Chen, Peng-Fei Qiu, Yong-Sheng Wang
RATIONALE: In addition to axillary lymph node (ALN), internal mammary lymph node (IMLN) is also the first-echelon drainage nodes reached by metastasising cancer cells from breast cancer, which can provide important prognostic information. PATIENT CONCERNS: In this paper, we will introduce a case of breast cancer patient whose postoperative pathology result showed that she had internal mammary sentinel lymph node (IMSLN) metastases but no axillary sentinel lymph node (ASLN) metastases...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29371927/independent-replication-of-polymorphisms-predicting-toxicity-in-breast-cancer-patients-randomized-between-dose-dense-and-docetaxel-containing-adjuvant-chemotherapy
#14
Annelot G J van Rossum, Marleen Kok, Danielle McCool, Mark Opdam, Nienke C Miltenburg, Ingrid A M Mandjes, Elise van Leeuwen-Stok, Alex L T Imholz, Johanneke E A Portielje, Monique M E M Bos, Aart van Bochove, Erik van Werkhoven, Marjanka K Schmidt, Hendrika M Oosterkamp, Sabine C Linn
Introduction: Although pharmacogenomics has evolved substantially, a predictive test for chemotherapy toxicity is still lacking. We compared the toxicity of adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC) and docetaxel-doxorubicin-cyclophosphamide (TAC) in a randomized multicenter phase III trial and replicated previously reported associations between genotypes and toxicity. Results: 646 patients (97%) were evaluable for toxicity (grade 2 and higher). Whereas AN was more frequent after ddAC ( P < 0...
December 26, 2017: Oncotarget
https://www.readbyqxmd.com/read/29361620/-i-dose-dense-chemotherapy-as-perioperative-treatment-in-breast-cancer
#15
Rika Kizawa, Yukinori Ozaki, Chihiro Kondoh, Yuko Tanabe, Toshimi Takano
No abstract text is available yet for this article.
December 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29317040/molecular-breast-imaging-a-comprehensive-review
#16
Ashley I Huppe, Anita K Mehta, Rachel F Brem
Molecular breast imaging (MBI), also called breast-specific gamma imaging (BSGI), has been an integral component of our breast imaging practice for over a decade. Unlike mammography and ultrasound that are based on anatomy, MBI is a physiologic approach to breast cancer detection. MBI detects additional foci of occult breast cancer in 9.0% of women with newly diagnosed breast cancer, has a high sensitivity for detecting high-risk lesions, and detects 98% of invasive breast cancer and 91.0% of ductal carcinoma in situ...
February 2018: Seminars in Ultrasound, CT, and MR
https://www.readbyqxmd.com/read/29275580/-response-and-prognosis-of-neoadjuvant-dose-dense-or-standard-schedule-chemotherapy-with-anthracyclines-and-taxanes-for-luminal-b-breast-cancer
#17
RANDOMIZED CONTROLLED TRIAL
A F Qiu, Z L Miao, G K Ge, C B Wang, J Bian, H Y Ma, Q Xu
Objective: To evaluate the efficacy and safety of neoadjuvant dose-dense or standard schedule chemotherapy with anthracyclines and taxanes for Luminal B (HER2-)Breast Cancer. Methods: From January 2010 to December 2014, 168 Luminal B (HER2-) breast cancer patients with stageⅡA-ⅢC confirmed by pathology were randomly assigned to receive one of the following regimens: (group A) concurrent TEC× 4 every 3 weeks, ( group B ) sequential EC× 4-T × 4 every 3 weeks, (group C ) dose-dense TEC× 4 every 2 weeks with G-CSF, (group D) sequential EC× 4(dose-dense)-T × 4 with dose-dense every 2 weeks ...
November 28, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29234253/evaluation-of-sentinel-lymph-node-biopsy-and-axillary-lymph-node-dissection-for-breast-cancer-treatment-concepts-a-retrospective-study-of-1-214-breast-cancer-patients
#18
Roland G Stein, Roland Fricker, Thomas Rink, Hartmut Fitz, Sebastian Blasius, Joachim Diessner, Sebastian F M Häusler, Tanja N Stüber, Victoria Andreas, Achim Wöckel, Thomas Müller
Background: Most breast cancer patients require lumpectomy with axillary sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). The ACOSOG Z0011-trial failed to detect significant effects of ALND on disease-free and overall survival among patients with limited sentinel lymph node (SLN) metastases. Intense dose-dense chemotherapy and supraclavicular fossa radiation (SFR) are indicated for patients with extensive axillary metastases. In this multicentered study, we investigated the relevance of ALND after positive SLNB to determine adequate adjuvant therapy...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29190004/long-term-safety-and-survival-outcomes-from-the-scandinavian-breast-group-2004-1-randomized-phase-ii-trial-of-tailored-dose-dense-adjuvant-chemotherapy-for-early-breast-cancer
#19
Alexios Matikas, Sara Margolin, Mats Hellström, Hemming Johansson, Nils-Olof Bengtsson, Lena Karlsson, Per Edlund, Per Karlsson, Elisabet Lidbrink, Barbro Linderholm, Henrik Lindman, Per Malmstrom, Kenneth Villman, Theodoros Foukakis, Jonas Bergh
PURPOSE: Although adjuvant polychemotherapy improves outcomes for early breast cancer, the significant variability in terms of pharmacokinetics results in differences in efficacy and both short and long-term toxicities. Retrospective studies support the use of dose tailoring according to the hematologic nadirs. METHODS: The SBG 2004-1 trial was a randomized feasibility phase II study which assessed tailored dose-dense epirubicin and cyclophosphamide (EC) followed by docetaxel (T) (group A), the same regimen with fixed doses (group B) and the TAC regimen (group C)...
April 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29108384/efficacy-safety-and-proper-dose-analysis-of-pegylated-granulocyte-colony-stimulating-factor-as-support-for-dose-dense-adjuvant-chemotherapy-in-node-positive-chinese-breast-cancer-patients
#20
Fan Zhang, RuiXia LingHu, XingYang Zhan, Ruisheng Li, Fan Feng, Xudong Gao, Lei Zhao, Junlan Yang
For high-risk breast cancer patients with positive axillary lymph nodes, dose-dense every-two-week epirubicin/cyclophosphamide-paclitaxel (ddEC-P) regimen is the optimal postoperative adjuvant therapy. However, this regimen is limited by the grade 3/4 neutropenia and febrile neutropenia (FN). There is an urgent need to explore the efficacy, safety and proper dosage of PEGylated granulocyte colony-stimulating factor (PEG-G-CSF) as support for ddEC-P in Chinese breast cancer patients with positive axillary lymph nodes...
October 3, 2017: Oncotarget
keyword
keyword
169092
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"